A recent study in colorectal cancer suggested that FSTL3 may contribute to immune evasion and showed that FSTL3 overexpression in malignant cells was linked to poor clinical survival outcomes with anti-PD1 therapy [21]. The gene discussed is FSTL3; the disease is colorectal cancer.